



# Market Announcement

2 June 2022

---

## ResApp Health Limited (ASX: RAP) – Suspension from Quotation

### Description

The securities of ResApp Health Limited ('RAP') will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in RAP by way of a Scheme of Arrangement.

### Issued by

**Raj Logarajah**

Adviser, Listings Compliance (Perth)

2 June 2022

Ms Barbara Lim  
ASX Listings Compliance  
Level 40, Central Park  
152-158 St Georges Terrace  
Perth WA 6000

By email: [tradinghaltspert@asx.com.au](mailto:tradinghaltspert@asx.com.au)

Dear Barbara

**RESAPP HEALTH LIMITED – VOLUNTARY SUSPENSION REQUEST**

Further to the request on 31 May 2022 for the securities of ResApp Health Limited (“**Company**”) to be placed in trading halt, the Company hereby requests that its securities be placed in voluntary suspension in accordance with ASX Listing Rule 17.2, pending the release of an announcement by the Company providing an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in the Company by way of a Scheme of Arrangement.

The Company requests that the voluntary suspension ends on the date the anticipated announcement referred to above is released to the market which the Company anticipates will occur by Monday 6 June 2022.

The Company is not aware of any reason why the voluntary suspension should not be granted, or of any other information necessary to inform the market about the suspension.

This request has been authorised for release to ASX by the Company's Board of Directors.

Yours faithfully



**Nicki Farley**  
**Company Secretary**  
**ResApp Health Limited**